Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month target prices for Amneal Pharmaceuticals' shares. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 164.4% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $4.79 on January 1st, 2022. Since then, AMRX shares have decreased by 56.6% and is now trading at $2.08.
View the best growth stocks for 2022 here.

Amneal Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 4,600,000 shares, an increase of 15.3% from the August 31st total of 3,990,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is presently 4.3 days. Approximately 4.7% of the company's shares are sold short.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its quarterly earnings results on Friday, August, 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by $0.03. The business had revenue of $559.40 million for the quarter, compared to the consensus estimate of $534.44 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 56.26% and a negative net margin of 6.29%. Amneal Pharmaceuticals's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.23 EPS.

Amneal Pharmaceuticals updated its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share guidance of $0.65-$0.70 for the period, compared to the consensus EPS estimate of $0.81. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.17 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $2.08.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $631.33 million and generates $2.09 billion in revenue each year. The company earns $10.62 million in net income (profit) each year or ($0.88) on an earnings per share basis.

The company employs 7,000 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.